A Phase 1a Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors

Administered By

Awarded By

Contributors

Start/End

  • October 23, 2017 - March 31, 2020